var data={"title":"Topiramate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Topiramate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7074?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">see &quot;Topiramate: Drug information&quot;</a> and <a href=\"topic.htm?path=topiramate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Topiramate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229206\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Qudexy XR;</li>\n      <li>Topamax;</li>\n      <li>Topamax Sprinkle;</li>\n      <li>Topiragen [DSC];</li>\n      <li>Trokendi XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229207\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Topamax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055790\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675768\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neonatal seizures; refractory:</b> Limited data available; efficacy results variable: Term neonate: Oral: Immediate release: 10 mg/kg/day was used in five neonates and 3 mg/kg/day was used in one neonate who were refractory to phenobarbital. In four of the five patients who received the higher dose, an absence or reduction in seizure frequency was observed; the neonate who received low dose (3 mg/kg) had no apparent change in seizures; no adverse effects noted required discontinuation of therapy (Glass 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuroprotectant following anoxic injury (with cooling):</b> Limited data available; efficacy results variable: Term neonate: Oral: Immediate release: 5 mg/kg/dose on day 1 followed by 3 mg/kg/dose once daily on day 2 and 3 was used in 11 neonates in study of safety; no adverse effects were noted (Filippi 2010). In an earlier pharmacokinetic pilot study of 13 neonates, the same investigators used 5 mg/kg/dose once daily for 3 days; results showed targeted serum concentrations (5 to 20 ng/mL) were achieved in 11 of 13 patients with some accumulation in patients treated with deep hypothermia (Filippi 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055783\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">see &quot;Topiramate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Do not abruptly discontinue therapy; taper dosage gradually to prevent rebound effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Infantile spasms:</b> Oral: Limited data available; dosing regimens variable. Consider twice-daily therapy once dose titration begins:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Newly diagnosed infantile spasm:</i> Weight-directed dosing: Infants and Children 3 to 24 months: Immediate release: Initial: 1 to 3 mg/kg/day administered as 1 or 2 daily doses; titrate every 3 to 7 days in 1 to 3 mg/kg/day increments as tolerated until seizures controlled; reported mean dose range: 9.1 to 14 mg/kg/day; reported range: 4 to 27 mg/kg/day. Dosing based on two small studies; first was an open-label trial of 15 pediatric patients (mean age: 8 months; age range: 4 to 14 months) with newly diagnosed infantile spasms which used an initial dose of 3 mg/kg/day in 2 divided doses; doses were increased by 3 mg/kg/day every 3 days until seizures were controlled or toxicity developed; mean dose required: 14 mg/kg/day (9 to 27 mg/kg/day); median rate of spasm reduction was 41% within the first 2 months of therapy with 20% of patients becoming spasm free (three of 15 patients) and 33% achieving a 50% reduction in spasm frequency (five of 15 patients) (Hosain, 2006). In another trial of 20 pediatric patients (median age: 6.5 months; range: 3 to 24 months) with newly diagnosed infantile spasms, an initial dose of 1 mg/kg/day was used; dose was increased by 1 mg/kg/day at weekly intervals until seizures were controlled up to a maximum daily dose: 12 mg/kg/day; reported mean stabilizing dose: 9.1 mg/kg/day (4 to 12 mg/kg/day); results showed 30% of patients became spasm free (six of 20 patients) and 70% achieved at least a 50% reduction in spasm frequency (Kwon, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Refractory:</i> Fixed dosing: Infants &ge;3 months to Children &le;4 years; weight &ge;7 kg: Immediate release: Initial: 25 mg/day once daily; titrate in 25 mg/day increments every 2 to 3 days as tolerated until seizures controlled up to a maximum daily dose: 24 mg/kg/day; dosing is from an open-label trial of 11 pediatric patients (mean age: 24 months) which reported a mean stabilizing dose of 15 mg/kg/day (8.3 to 23.7 mg/kg/day); results showed statistically significant decrease in spasm frequency with 45% of patients becoming spasm free (Glauser, 1998). In an extension phase of this study in eight of the initial subjects, the mean dose was 29 mg/kg/day (maximum daily dose: 50 mg/kg/day); 50% of the remaining patients (four of eight) were seizure free and all patients except one maintained a &ge;50% reduction in spasm frequency (Glauser, 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anticonvulsant, adjunctive therapy:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 2 to 16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Partial onset seizures or Lennox-Gastaut syndrome:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Immediate release: Children and Adolescents 2 to 16 years: Initial: 1 to 3 mg/kg/day (maximum dose: 25 mg/dose) administered nightly for 1 week; increase at 1- to 2-week intervals in increments of 1 to 3 mg/kg/day in 2 divided doses; titrate dose to response; usual maintenance: 5 to 9 mg/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Qudexy XR: Children and Adolescents 2 to 16 years: Initial: 25 mg once daily (approximately 1 to 3 mg/kg/day) administered nightly for 1 week; increase at 1- to 2-week intervals in increments of 1 to 3 mg/kg/day rounded to the nearest appropriate capsule size administered once daily; titrate dose to response; usual maintenance: 5 to 9 mg/kg/dose once daily; range: 5 to 9 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Trokendi XR: Children and Adolescents 6 to 16 years, able to swallow capsule whole: Initial: 25 mg once daily (approximately 1 to 3 mg/kg/day) administered nightly for 1 week; increase at 1- to 2-week intervals in increments of 1 to 3 mg/kg/day rounded to the nearest appropriate capsule size administered once daily; titrate dose to response; usual maintenance: 5 to 9 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Primary generalized tonic-clonic seizures:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Immediate release: Children and Adolescents 2 to 16 years: Initial: 1 to 3 mg/kg/day (maximum dose: 25 mg/dose) administered nightly for 1 week; increase over 8 weeks in increments of 1 to 3 mg/kg/day in 2 divided doses to a target dose of 6 mg/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Qudexy XR: Children and Adolescents 2 to 16 years: Initial: 25 mg once daily (approximately 1 to 3 mg/kg/day) administered nightly for 1 week; increase over 8 weeks in increments of 1 to 3 mg/kg/day rounded to the nearest appropriate capsule size to a target dose of 6 mg/kg/day once daily; range: 5 to 9 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Trokendi XR: Children and Adolescents 6 to 16 years, able to swallow capsule whole: Initial: 25 mg once daily (approximately 1 to 3 mg/kg/day) administered nightly for 1 week; increase over 8 weeks in increments of 1 to 3 mg/kg/day rounded to the nearest appropriate capsule size to a target dose of 6 mg/kg/day once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Partial onset seizures or Lennox-Gastaut syndrome:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Immediate release: Initial: 25 to 50 mg/day administered daily for 1 week; increase at weekly intervals by 25 to 50 mg/day; administer in 2 divided doses; titrate dose to response; usual maintenance dose: 100 to 200 mg twice daily; maximum daily dose: 1600 mg/<b>day</b>; <b> Note:</b> Doses above 400 mg/day have not been shown to increase efficacy in dose-response studies in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Extended release: Quedexy XR, Trokendi XR: Initial: 25 to 50 mg once daily for 1 week; increase at weekly intervals by 25 to 50 mg/day once daily; titrate dose to response; longer intervals between dosage adjustment may be used; usual maintenance dose: 200 to 400 mg once daily; maximum daily dose: 1600 mg/<b>day</b>; higher doses have not been studied</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Primary generalized tonic-clonic seizures:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Immediate release: Initial: 25 to 50 mg/day once daily for 1 week; increase over 8 weeks in increments of 25 to 50 mg/day in 2 divided doses; titrate dose to response; usual maintenance dose: 200 mg twice daily; use slower initial titration rate (&gt;2 week intervals); maximum daily dose: 1600 mg/<b>day</b>; <b>Note:</b> Doses above 400 mg/day have not been shown to increase efficacy in dose-response studies in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Extended release: Qudexy XR, Trokendi XR: Initial: 25 mg to 50 mg once daily for 1 week; increase at weekly intervals by 25 to 50 mg/day increments once daily; titrate dose to response; usual maintenance dose: 400 mg once daily; maximum daily dose: 1600 mg/<b>day</b>; higher doses have not been studied</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anticonvulsant, monotherapy: Partial onset seizures or primary generalized tonic-clonic seizures:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to &lt;10 years: Initial: 25 mg once daily (in evening); may increase if tolerated to 25 mg twice daily in week 2; thereafter, may increase by 25 to 50 mg/day at weekly intervals over 5 to 7 weeks up to the lower end of the target daily maintenance dosing range (ie, to the minimum recommended maintenance dose); if additional seizure control is needed and therapy is tolerated, may further increase by 25 to 50 mg/day at weekly intervals up to the upper end of the target daily maintenance dosing range (ie, to the maximum recommended maintenance dose):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Target daily maintenance dosing range:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&le;11 kg: 150 to 250 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">12 to 22 kg: 200 to 300 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">23 to 31 kg: 200 to 350 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">32 to 38 kg: 250 to 350 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;38 kg: 250 to 400 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;10 years and Adolescents: Initial: 25 mg twice daily; increase at weekly intervals by 50 mg/day increments up to a dose of 100 mg twice daily (week 4 dose); thereafter, may further increase at weekly intervals by 100 mg/day increments up to the recommended maximum dose of 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Qudexy XR, Trokendi XR: Children &ge;10 years and Adolescents: Initial: 50 mg once daily for 1 week; increase at weekly intervals by 50 mg/day increments up to a dose of 200 mg once daily (week 4 dose); thereafter, may increase at weekly intervals by 100 mg/day increments up to the recommended dose of 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Migraine prophylaxis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to &lt;12 years; weight: &ge;20 kg: Limited data available: Immediate release: Initial: 15 mg once daily for 1 week; then increase to 15 mg twice daily for 1 week; then increase to 25 mg twice daily for 7 days; continue to gradually titrate to effect up to target dose of 2 to 3 mg/kg/day divided twice daily; maximum daily dose: 200 mg/<b>day</b>; dosing based on a double-randomized, placebo-controlled trial of 90 pediatric patients &lt;12 years (treatment arm: n=59; mean age: 11.3 years as part of a larger trial with a total of 108 pediatric patients receiving topiramate compared to 49 receiving placebo) which showed a mean reduction in migraine days/month with topiramate and significantly more topiramate patients experienced &ge;75% reduction in mean monthly migraine days compared to placebo (32% vs 14%) for overall study population; mean maintenance dose: 2 mg/kg/day; treatment duration of maintenance dose: 12 weeks (Winner, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Initial: 25 mg/day once daily at night for 1 week; increase at weekly intervals in 25 mg/day increments as tolerated and indicated to recommended dose of 50 mg twice daily; in a double-blind, placebo-controlled, dose-finding trial of 103 pediatric patients &ge;12 years (mean age: 14.2 years), the daily dose of 100 mg/day was shown to significantly decrease frequency of migraine attacks compared to a lower dose of 50 mg/day (Lewis, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Do not abruptly discontinue therapy; taper dosage gradually to prevent rebound effects. In clinical trials, adult doses were withdrawn by decreasing in weekly intervals of 50-100 mg/day gradually over 2 to 8 weeks for seizure treatment, and by decreasing in weekly intervals by 25-50 mg/day for migraine prophylaxis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Epilepsy, monotherapy:</b> Partial onset seizure and primary generalized tonic-clonic seizure: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Initial: 25 mg twice daily; may increase weekly by 50 mg daily up to 100 mg twice daily (week 4 dose); thereafter, may further increase weekly by 100 mg daily up to the recommended dose of 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Initial: 50 mg daily for 1 week; may increase weekly by 50 mg daily up to 200 mg once daily (week 4 dose); thereafter, may further increase weekly by 100 mg daily up to the recommended dose of 400 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Epilepsy, adjunctive therapy:</b> Partial onset seizure, primary generalized tonic-clonic seizure, Lennox-Gastaut syndrome: Oral: <b>Note</b>: Doses &gt;1600 mg have not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Initial: 25 mg once or twice daily for 1 week; may increase weekly by 25 to 50 mg daily until response; usual maintenance dose: 100 to 200 mg twice daily (partial-onset seizures) or 200 mg twice daily (primary generalized tonic-clonic seizures). Doses &gt;400 mg have not shown additional benefit for treatment of partial-onset seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Initial: 25 to 50 mg once daily for 1 week; may increase weekly by 25 to 50 mg daily until response; usual maintenance dose: 200 to 400 mg once daily (partial-onset seizures, Lennox-Gastaut syndrome) or 400 mg once daily (primary generalized tonic-clonic seizures). Doses &gt;400 mg daily have not shown additional benefit for treatment of partial-onset seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Migraine prophylaxis:</b> Oral: Immediate release: Initial: 25 mg once daily (in evening); may increase weekly by 25 mg daily up to the recommended dose of 100 mg daily in 2 divided doses. Increased intervals between dose adjustments may be considered. Doses &gt;100 mg daily have shown no additional benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 25% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis/peritoneal dialysis (PD): Administer 25% of dose; supplemental dose after hemodialysis needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Manufacturer's labeling: CrCl &lt;70 mL/minute/1.73 m<sup>2</sup>: Administer 50% of the usual dose; titrate more slowly due to prolonged half-life; significantly hemodialyzed; cleared by hemodialysis at a rate that is 4 to 6 times greater than a normal individual; supplemental doses may be required</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, clearance may be reduced. Carefully adjust dose as plasma concentrations may be increased if normal dosing is used.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229180\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule ER 24 Hour Sprinkle, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qudexy XR: 25 mg (30 ea, 500 ea [DSC]); 50 mg (30 ea, 500 ea [DSC]); 100 mg (30 ea, 500 ea [DSC]); 150 mg (30 ea, 500 ea [DSC]); 200 mg (30 ea, 500 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg (30 ea, 500 ea [DSC]); 50 mg (30 ea, 500 ea [DSC]); 100 mg (30 ea, 500 ea [DSC]); 150 mg (30 ea, 500 ea [DSC]); 200 mg (30 ea, 500 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trokendi XR: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trokendi XR: 50 mg, 100 mg, 200 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #6 (sunset yellow), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Sprinkle, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topamax Sprinkle: 15 mg, 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topamax: 25 mg, 50 mg, 100 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topiragen: 25 mg [DSC], 50 mg [DSC], 100 mg [DSC], 200 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg, 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229165\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874884\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Qudexy XR: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205122s003s005lbl.pdf#page=69&amp;token=mS8d2NOSGey35PLAjNd4z5jDHRYbqVWPRv6db+Nn+7A2T8GCHpkcFaH5C9afxvNIZ4NMIPayD6jHU4Y8YuiMi4LvJCWBy1UVXe9t9e5oZLc2SXRQ+b7brw40CMUT1yoJ&amp;TOPIC_ID=12851\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205122s003s005lbl.pdf#page=69</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topamax: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020505s057_020844s048lbl.pdf#page=50&amp;token=DsUtD28FbtieUqHJ3rW8dUtaS/738nzWLlICLUHiBZ4QkatkmrjfjcIfZVyOSZI4Mczaq45H5GRZzc+yuWEKbkCDNZSyLHqH3+wVFwh9lGrA2kDzb2IlVMPfvVl2PXfQ&amp;TOPIC_ID=12851\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020505s057_020844s048lbl.pdf#page=50</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Trokendi XR: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201635s011s017lbl.pdf#page=58&amp;token=vpXvHZAcwGX+kcnVpwuXisDFCgneVP2MNpYNTUnIyXdc4ym+3pO/bLVpq6j0RLoy5GdL/e/kDqN4y0gdBo0g6pClMiFISmbFB+VUoac/8tydzjZ4UL04fNHXnLtlkTRJ&amp;TOPIC_ID=12851\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201635s011s017lbl.pdf#page=58</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055795\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered without regard to food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets: Broken tablets have a bitter taste; tablets may be crushed, mixed with water, and administered immediately. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sprinkle capsules: Swallow sprinkle capsules whole or open and sprinkle contents on small amount of soft food (eg, 1 teaspoonful of applesauce, oatmeal, ice cream, pudding, custard, or yogurt); swallow sprinkle/food mixture immediately; do not chew; do not store for later use; drink fluids after dose to make sure mixture is completely swallowed. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Qudexy XR: May be swallowed whole or may be opened and sprinkled on a small amount (~1 teaspoon) of soft food; swallow immediately and do not chew.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Trokendi XR: Swallow capsules whole; do not sprinkle capsules on food, chew, or crush. Avoid alcohol use with within 6 hours prior to and 6 hours after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132845\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229201\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Extended release capsules: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Sprinkle capsules: Store at or below 25&deg;C (77&deg;F). Protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablets: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055794\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Topamax: Initial monotherapy of primary generalized tonic-clonic seizures or partial onset seizures (FDA approved in ages &ge;2 years and adults); adjunctive treatment of primary generalized tonic-clonic seizures or partial onset seizures (FDA approved in ages &ge;2 years and adults); adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (FDA approved in ages &ge;2 years); prophylaxis of migraine headache (FDA approved in ages &ge;12 years and adults); has also been used for infantile spasms </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Qudexy XR, Trokendi XR: Initial monotherapy of primary generalized tonic-clonic seizures or partial onset seizures (FDA approved in ages &ge;10 years and adults); adjunctive treatment of primary generalized tonic-clonic seizures or partial onset seizures (Qudexy XR: FDA approved in ages &ge;2 years and adults; Trokendi XR: FDA approved in ages &ge;6 years and adults); adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (Qudexy XR: FDA approved in ages &ge;2 years and adults; Trokendi XR: FDA approved in ages &ge;6 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229250\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Topamax may be confused with Sporanox, TEGretol, TEGretol-XR, Toprol-XL</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bioequivalence has not been demonstrated between Trokendi XR and Qudexy XR.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Qudexy XR capsules may be opened to sprinkle the entire contents on a small amount (~1 teaspoon) of soft food. Do not open and sprinkle Trokendi XR capsules on food, chew, or crush; doing so may disrupt the tri-phasic release properties.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Avoid alcohol use with Trokendi XR within 6 hours prior to and 6 hours after administration; concurrent use may result in dose dumping.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229248\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events are reported for adult and pediatric patients for various indications and regimens. <b>Note:</b> A wide range of dosages were studied. Incidence of adverse events was frequently lower in the pediatric population studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain (adults), flushing (children &amp; adolescents), hypotension, orthostatic hypotension, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation (adolescents &amp; adults), anxiety (adolescents &amp; adults), ataxia (adolescents &amp; adults), attempted suicide, behavioral problems (children &amp; adolescents), cognitive dysfunction, confusion, depression, disturbance in attention, dizziness (adolescents &amp; adults), drowsiness (adolescents &amp; adults), exacerbation of depression (adolescents &amp; adults), fatigue, headache (children and adolescents), hypertonia (adults), hypoesthesia (adolescents &amp; adults), insomnia (adolescents &amp; adults), lack of concentration, memory impairment, mood disorder, nervousness (adolescents &amp; adults), paresthesia (more common in adolescents &amp; adults), psychomotor retardation (adolescents &amp; adults), speech disturbance (adolescents &amp; adults), suicidal ideation, suicidal tendencies, vertigo (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris (adults), alopecia, pruritus (adolescents &amp; adults), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased serum bicarbonate (more common in adolescents &amp; adults), hyperammonemia (adolescents), hyperchloremia (children &amp; adolescents), increased gamma-glutamyl transferase (adults), increased serum total protein (children &amp; adolescents), increased thirst (adolescents &amp; adults), increased uric acid (children &amp; adolescents), intermenstrual bleeding (children and adolescents), menstrual disease (adolescents &amp; adults), weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (adolescents &amp; adults), ageusia (adolescents &amp; adults), anorexia (adolescents &amp; adults), constipation (adolescents &amp; adults), diarrhea, dysgeusia (adolescents &amp; adults), dyspepsia (adolescents &amp; adults), gastroenteritis (adolescents &amp; adults), gastritis (adults), gastroesophageal reflux disease (adults), gingival hemorrhage, hematuria, nausea (adolescents &amp; adults), xerostomia (adolescents &amp; adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Cystitis (adults), decreased libido (adults), dysuria (adults), premature ejaculation (adolescents &amp; adults), urinary frequency, urinary incontinence (children &amp; adolescents), urinary tract infection (adolescents &amp; adults), vaginal hemorrhage (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Abnormal phosphorus levels (decreased; children &amp; adolescents), anemia (children &amp; adolescents), change in platelet count (increased; children &amp; adolescents), decreased neutrophils (children &amp; adolescents), decreased white blood cell count (children &amp; adolescents), eosinophilia, hemorrhage, neoplasm (adolescents &amp; adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction (adolescents &amp; adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (adolescents &amp; adults), leg pain (adolescents &amp; adults), muscle spasm, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision (adolescents &amp; adults), conjunctivitis (adolescents &amp; adults), myopia, scotoma, visual disturbance (adolescents &amp; adults), visual field defect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis media (adolescents &amp; adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen (children &amp; adolescents), increased serum creatinine (children &amp; adolescents), nephrolithiasis (adolescents &amp; adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough (adolescents &amp; adults), dyspnea (adolescents &amp; adults), epistaxis (children and adolescents), pharyngitis (adolescents &amp; adults), rhinitis, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Accidental injury (adolescents &amp; adults), fever, language problems (adolescents &amp; adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute myopia with secondary angle-closure glaucoma, bullous rash, erythema multiforme, hepatic failure, hepatitis, hyperammonemic encephalopathy, hyperchloremic metabolic acidosis (nonanion gap), hyperthermia, hypohidrosis, maculopathy, major hemorrhage (children), pancreatitis, pemphigus, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229187\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Recent alcohol use (ie, within 6 hours prior to and 6 hours after administration) (Trokendi XR only); patients with metabolic acidosis who are taking concomitant metformin (Qudexy XR only).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to topiramate or any component of the formulation or container; pregnancy and women in childbearing years not using effective contraception (migraine prophylaxis only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229169\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Cognitive dysfunction (confusion, psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech or language problems), psychiatric disturbances (depression or mood disorders), and sedation (somnolence or fatigue) may occur with use; incidence may be related to rapid titration and higher doses; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). May also cause paresthesia, dizziness, and ataxia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperammonemia/encephalopathy: Hyperammonemia with or without encephalopathy may occur with monotherapy or in combination with valproic acid and has been documented in patients who have tolerated each drug alone; incidence may be dose-related. Risk may be increased in patients with inborn errors of metabolism or decreased hepatic mitochondrial activity. May be asymptomatic; monitor for lethargy, vomiting, or unexplained changes in mental status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Metabolic acidosis: May be associated with hyperchloremic nonanion gap metabolic acidosis due to inhibition of carbonic anhydrase and increased renal bicarbonate loss. Decreases in serum bicarbonate are relatively common (up to 67% of epilepsy patients and 77% of migraine patients) but usually mild-to-moderate (average decrease of 4 mEq/L at dose of 400 mg/day in adults and 6 mg/kg/day in children). However, risk may be increased in patients with a predisposing condition (renal, respiratory and/or hepatic impairment), diarrhea, ketogenic diet, status epilepticus, or concurrent treatment with other drugs which may cause acidosis. Metabolic acidosis may occur at dosages as low as 50 mg/day. Serum bicarbonate should be monitored, as well as potential complications of chronic acidosis (nephrolithiasis, nephrocalcinosis, osteomalacia/osteoporosis, and reduced growth rates and/or reduced weight in children). Dose reduction or discontinuation (by tapering dose) should be considered in patients with persistent or severe metabolic acidosis. If treatment is continued, alkali supplementation should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oligohidrosis/hyperthermia: May be associated with oligohidrosis and hyperthermia, most frequently in children; use caution and monitor closely during strenuous exercise, during exposure to high environmental temperature, or in patients receiving other carbonic anhydrase inhibitors and drugs with anticholinergic activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic effects: Has been associated with acute myopia and secondary angle-closure glaucoma in adults and children, typically within 1 month of initiation; discontinue in patients with acute onset of decreased visual acuity and/or ocular pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal calculus: Topiramate exhibits weak carbonic anhydrase inhibitory properties and may increase the risk of kidney stones about 2 to 4 times that of the untreated population. Kidney stones have been reported in children and adults (incidence higher in males). Consider avoiding use in patients on a ketogenic diet. The risk of kidney stones may be reduced by increasing fluid intake.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual field defects: Has been reported independent of increased intraocular pressure; generally reversible upon discontinuation. Consider discontinuation if visual problems occur at any time during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in patients with depression or suicidal tendencies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Eating disorders: The exacerbation and development of eating disorders, including anorexia nervosa and bulimia, has been reported in case reports of adolescents receiving topiramate for migraines or chronic headaches and an adult receiving topiramate for epilepsy. Prior to initiation of topiramate screen for a history of eating disorder symptoms, eating disorder risk factors (eg, history of dieting behavior), cognitive symptoms of eating disorders (eg, weight or shape concerns, fear of gaining weight, drive for thinness), and any recent changes in social functioning including increased withdrawal or isolation. Inquire whether the patient has unrealistic or unhealthy weight goals. Evaluate exercise habits (eg, look for over-exercising or compulsive exercising above that of similarly athletic peers) and dietary intake; assess rigid patterns or avoidance of specific categories of foods and preoccupation with maintaining a &ldquo;healthy diet&rdquo; or experimentation with fad diets. In adolescents assess developmental weight history with growth curves. Monitor eating behaviors and weight closely in patients receiving topiramate who have eating disorder symptoms or risk factors (Lebow 2015; Rosenow 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution with hepatic impairment; clearance may be reduced. Dosage adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution with renal impairment; clearance may be reduced. Dosage adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; dosage adjustment may be necessary. Weight loss, cognitive impairment, sedation, and gait/balance disturbances may be more pronounced in the older adult cohort (Sommer 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Do not discontinue abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Doses were also gradually withdrawn in migraine prophylaxis studies (decreased in weekly intervals by 25-50 mg/day).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25955898\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\"> In pediatric clinical trials for adjunctive treatment of seizures, persistent decreases in serum bicarbonate occurred in 67% of patients receiving topiramate (versus 10% of those receiving placebo). Markedly low serum bicarbonate values were reported in 11% of pediatric patients receiving topiramate (versus 0% of those receiving placebo). In pediatric monotherapy trials, persistent decreases in serum bicarbonate occurred in 9% of patients receiving 50 mg/day and 25% of patients receiving 400 mg/day. Markedly low serum bicarbonate values were reported in 1% to 6% of pediatric patients receiving topiramate monotherapy. The risk of topiramate-induced metabolic acidosis may be increased in patients with predisposing conditions (eg, diarrhea, status epilepticus, hepatic impairment, renal dysfunction, severe respiratory disorders, ketogenic diet, surgery) or concurrent treatment with other drugs that may cause acidosis. Metabolic acidosis may be more common and more severe in infants and children &lt;2 years of age with up to 45% of patients receiving 25 mg/kg/day developing metabolic acidosis in clinical trials. Monitor for potential complications of chronic acidosis including nephrolithiasis, nephrocalcinosis, osteomalacia/osteoporosis, and reduction in growth rates (including weight). Reductions in Z scores (from baseline) for length, weight, and head circumference were observed in infants and toddlers who received long-term topiramate (for up to 1 year) for intractable partial epilepsy; reductions in Z scores for length and weight correlated to the severity of metabolic acidosis. Serum bicarbonate should be monitored at baseline and periodically during topiramate therapy. The most common adverse effects of topiramate observed in children include the following: Anorexia, cognitive problems, dizziness, fatigue, fever, flushing, headache, mood problems, parethesia, somnolence, and weight loss; neuropsychiatric and cognitive adverse effects were reported with a lower incidence in children than adults. Pediatric patients &lt;24 months of age may be at increased risk for topiramate-associated hyperammonemia, especially when used concurrently with valproic acid; monitor closely for lethargy, vomiting, or unexplained changes in mental status.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Risk of nephrolithiasis (kidney stones) is higher in children; reported incidence in adults: 1.5%; in pediatric patients &lt;24 months with long-term use (up to 1 year): 7% (kidney or bladder stones); one retrospective study evaluating long-term use (1 year) in children with epilepsy (n=96; mean age: 6.9 &plusmn; 3.8 years) reported an incidence of 5.2% (Mahmoud, 2011); risk may be increased with ketogenic diet or concomitant drugs that produce metabolic acidosis; avoid use while on topiramate therapy; maintain adequate hydration during therapy; monitor for signs or symptoms of kidney or bladder or kidney stone development. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Extended release dosage forms (Qudexy XR and Trokendi XR) are not bioequivalent and should not be interchanged. Qudexy XR capsules may be opened and contents sprinkled on a small amount (~1 teaspoon) of soft food. Do not open and sprinkle Trokendi XR capsules on food, nor chew or crush; doing so may disrupt the triphasic release properties.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229235\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229174\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12851&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Topiramate. Alcohol (Ethyl) may increase the serum concentration of Topiramate. This applies specifically to use with the extended-release topiramate capsules (Trokendi XR).  Also, topiramate concentrations may be subtherapeutic in the later portion of the dosage interval. Management: Concurrent use of alcohol within 6 hours of ingestion of extended-release topiramate (Trokendi XR) is contraindicated.  Any use of alcohol with topiramate should be avoided when possible and should only be undertaken with extreme caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Carbonic Anhydrase Inhibitors may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amitriptyline: Topiramate may enhance the CNS depressant effect of Amitriptyline. Topiramate may increase serum concentrations of the active metabolite(s) of Amitriptyline. Topiramate may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Topiramate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Topiramate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Topiramate may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Topiramate may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the hypokalemic effect of Topiramate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Topiramate may enhance the adverse/toxic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Topiramate may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: Topiramate may decrease the serum concentration of Pioglitazone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Topiramate may decrease the serum concentration of Progestins (Contraceptive).  Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated.  If another combination is used, monitor patients closely for adverse effects.  Tachypnea, anorexia, lethargy, and coma have been reported.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypokalemic effect of Topiramate. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Topiramate. Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Topiramate may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Topiramate may enhance the adverse/toxic effect of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229202\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Ketogenic diet may increase the possibility of acidosis and/or kidney stones. Management: Monitor for symptoms of acidosis or kidney stones.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229176\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229191\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on limited data (n=5), topiramate was found to cross the placenta and could be detected in neonatal serum (Ohman 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Topiramate may cause fetal harm if administered to a pregnant woman. An increased risk of oral clefts (cleft lip and/or palate) and for being small for gestational age (SGA) has been observed following in utero exposure. Data from the North American Antiepileptic Drug (NAAED) Pregnancy Registry reported that the prevalence of oral clefts was 1.1% for infants exposed to topiramate during the first trimester of pregnancy, versus 0.36% for infants exposed to a reference antiepileptic drug, and 0.12% for infants with no exposure born to mothers without epilepsy; the relative risk of oral clefts in infants exposed to topiramate was calculated to be 9.6 (95% CI: 4 to 23). Data from the NAAED Pregnancy Registry reported that the prevalence of small for gestational age newborns was 19.7% for newborns exposed to topiramate in utero, versus 7.9% for newborns exposed to a reference antiepileptic drug, and 5.4% for newborns with no exposure born to mothers without epilepsy. Although not evaluated during pregnancy, metabolic acidosis may be induced by topiramate. Metabolic acidosis during pregnancy may result in adverse effects and fetal death. Pregnant women and their newborns should be monitored for metabolic acidosis. In general, maternal polytherapy with antiepileptic drugs may increase the risk of congenital malformations; monotherapy with the lowest effective dose is recommended. Newborns of women taking antiepileptic medications may be at an increased risk of a 1 minute APGAR score &lt;7 (Harden 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Maternal serum concentrations may decrease during the second and third trimesters of pregnancy; therefore, therapeutic drug monitoring should be considered during pregnancy and postpartum in patients who require therapy (Ohman 2009; Westin 2009). Effective contraception should be used in women who are not planning a pregnancy; consider use of alternative medications in women who wish to become pregnant.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Data collection to monitor pregnancy and infant outcomes following exposure to topiramate is ongoing. Patients may enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055789\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency, duration, and severity of seizure episodes or migraine headaches; renal function; monitor serum electrolytes including baseline and periodic serum bicarbonate, symptoms of metabolic acidosis, complications of chronic acidosis (eg, nephrolithiasis, rickets, and reduced growth rates); monitor body temperature and for decreased sweating, especially in warm or hot weather; monitor serum ammonia concentration in patients with unexplained lethargy, vomiting, or mental status changes; intraocular pressure, symptoms of secondary angle closure glaucoma; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055793\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Not applicable; plasma topiramate concentrations have not been shown to correlate with clinical efficacy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229168\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Anticonvulsant activity may be due to a combination of potential mechanisms: Blocks neuronal voltage-dependent sodium channels, enhances GABA(A) activity, antagonizes AMPA/kainate glutamate receptors, and weakly inhibits carbonic anhydrase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229186\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Immediate release preparations are bioequivalent (sprinkle capsule and tablet); extended release capsules (Trokendi XR) administered once daily is bioequivalent to twice daily administration of immediate release formulations. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Good, rapid; immediate release formulation is unaffected by food. A single Trokendi XR dose with a high-fat meal increased the C<sub>max</sub> by 37% and shortened the T<sub>max</sub> to approximately 8 hours; this effect is significantly reduced following repeat administrations. A single Qudexy XR dose with a high-fat meal delayed the T<sub>max</sub> by 4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d:</sub> 0.6 to 0.8 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 15% to 41% (inversely related to plasma concentrations) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minor amounts metabolized in liver via hydroxylation, hydrolysis, and glucuronidation; there is evidence of renal tubular reabsorption; percentage of dose metabolized in liver and clearance are increased in patients receiving enzyme inducers (eg, carbamazepine, phenytoin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~80% (immediate release)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Not receiving concomitant enzyme inducers or valproic acid: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Neonates (full-term) with hypothermia: ~43 hours (Fillipi 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children 9 months to &lt;4 years: 10.4 hours (range: 8.5 to 15.3 hours) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 4 to 7 years: Mean range: 7.7 to 8 hours (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 8 to 11 years: Mean range: 11.3 to 11.7 hours (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children and Adolescents 12 to 17 years: Mean range: 12.3 to 12.8 hours (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Receiving concomitant enzyme inducers (eg, carbamazepine, phenytoin, phenobarbital):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\"> Neonates (full-term) with hypothermia: 26.5 hours (Fillipi 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children 9 months to &lt;4 years: 6.5 hours (range: 3.75 to 10.2 hours) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children and Adolescents 4 to 17 years: 7.5 hours (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Receiving valproic acid: Infants and Children 9 months to 4 years: 9.2 hours (range: 7.23 to 12 hours) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 19 to 23 hours (mean: 21 hours) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults with renal impairment: 59 &plusmn; 11 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: Qudexy XR: ~56 hours; Trokendi XR: ~31 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates (full-term) with hypothermia: 3.8 hours (Fillipi 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 9 months to &lt;4 years: 3.7 hours (range: 1.5 to 10.2 hours) (Michealoff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 4 to 17 years: Mean range: 1 to 2.8 hours (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 2 hours; range: 1.4 to 4.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release: Qudexy XR: ~20 hours; Trokendi XR: ~24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~70% as unchanged drug); may undergo renal tubular reabsorption </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Not receiving concomitant enzyme inducers or valproic acid: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates (full-term) with hypothermia: 13.4 mL/kg/hour (Fillipi 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 9 months to &lt;4 years: 46.5 mL/kg/hour (range: 30.5 to 70.9 mL/kg/hour) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 4 to 17 years: 27.6 mL/kg/hour (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Receiving concomitant enzyme inducers: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates (full-term) with hypothermia: 17.9 mL/kg/hour (Fillipi 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 9 months to &lt;4 years: 85.4 mL/kg/hour (range: 46.2 to 135 mL/kg/hour) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents 4 to 17 years: 60.6 mL/kg/hour (Rosenfeld 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Receiving valproic acid: Infants and Children 9 months to &lt;4 years: 49.6 mL/kg/hour (range: 26.6 to 60.2 mL/kg/h) (Mikaeloff 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 20 to 30 mL/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11509771\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>20 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 6 mg/mL topiramate oral suspension may be made with tablets and one of two different vehicles (a 1:1 mixture of Ora-Sweet and Ora-Plus, or a mixture of Simple Syrup, NF and methylcellulose 1% with parabens). Crush six 100 mg tablets in a mortar and reduce to a fine powder. Add a small amount of methylcellulose gel and mix to a uniform paste (<b>Note:</b> Use a small amount of methylcellulose gel when using the 1:1 Ora-Sweet and Ora-Plus mixture as the vehicle; use 10 mL methylcellulose 1% with parabens when using Simple Syrup, NF as the vehicle); mix while adding the chosen vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a graduated cylinder; rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Store in plastic prescription bottles; label &quot;shake well&quot; and &quot;refrigerate.&quot; Stable for 90 days refrigerated (preferred) or at room temperature.</p>\n    <div class=\"reference\">Allen LV Jr. Contemporary compounding: topiramate 20 mg/mL oral suspension. <i>U.S. Pharmacist. </i>2017;42(5):46-47.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229190\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Sprinkle</b> (Qudexy XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $255.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $332.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $659.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $811.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $902.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Sprinkle</b> (Topiramate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $215.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $280.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $556.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $683.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $760.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Trokendi XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $318.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $415.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $822.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $1,124.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, sprinkles</b> (Topamax Sprinkle Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (60): $387.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $468.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, sprinkles</b> (Topiramate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (60): $144.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $175.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Topamax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $409.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $817.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $1,116.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $1,307.23</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Topiramate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $152.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $302.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $413.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $483.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229193\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acomicil (ES);</li>\n      <li>Epilramate (TW);</li>\n      <li>Epimat (UA);</li>\n      <li>Epimate (LK, PH);</li>\n      <li>Epitomax (FI, FR);</li>\n      <li>Epitop (PH);</li>\n      <li>Etopira (BD);</li>\n      <li>Fagodol (ES);</li>\n      <li>Gabatopa (KR);</li>\n      <li>Ipramax (QA);</li>\n      <li>Moramax (TH);</li>\n      <li>Piramed (BD);</li>\n      <li>Pradox (TH);</li>\n      <li>Rondigal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Seziril (LK);</li>\n      <li>Tamate (AU);</li>\n      <li>Tiramate (NZ);</li>\n      <li>Topamac (AR, CO, EC, IN, PE, PY, UY);</li>\n      <li>Topamaks (UA);</li>\n      <li>Topamax (AE, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CY, CZ, DE, EE, EG, ES, FI, GB, HK, HR, IE, IL, IQ, IR, IT, JM, JO, KR, KW, LB, LK, LT, LU, LV, LY, MT, MX, MY, NL, NZ, OM, PH, PK, PL, PT, QA, RO, RU, SA, SG, SI, SK, SY, TH, TR, TW, VE, VN, YE, ZA);</li>\n      <li>Topamax Sprinkle (AE, BB, BH, CY, HK, IL, KR, KW, NZ, SA);</li>\n      <li>Topictal (CR, DO, EC, GT, HN, NI, PA, PY, SV);</li>\n      <li>Topimax (CR, DK, DO, GT, HN, IS, NI, NO, PA, SE, SV);</li>\n      <li>Topina (JP);</li>\n      <li>Topinmate (TW);</li>\n      <li>Topirol (PH);</li>\n      <li>Topiron (KR);</li>\n      <li>Topirva (BD);</li>\n      <li>Topitrim (IL);</li>\n      <li>Topmate (BD, KR);</li>\n      <li>Topomac (GR);</li>\n      <li>Toprakar (UA);</li>\n      <li>Topvex (PH);</li>\n      <li>Toramate (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brandes JL, Saper JR, Diamond M, et al, &ldquo;Topiramate for Migraine Prevention: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2004, 291(8):965-73. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/14982912/pubmed\" target=\"_blank\" id=\"14982912\">14982912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al, &quot;Guidelines For the Evaluation and Management of Status Epilepticus,&quot; <i>Neurocrit Care</i>, 2012, 17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doose DR, Walker SA, Gisclon LG, et al, &ldquo;Single-Dose Pharmacokinetics and Effect of Food on the Bioavailability of Topiramate, a Novel Antiepileptic Drug,&rdquo; <i>J Clin Pharmacol</i>, 1996, 36(10):884-91. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/ 8930774 /pubmed\" target=\"_blank\" id=\" 8930774 \"> 8930774 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filippi L, la Marca G, Fiorini P, et al, &quot;Topiramate Concentrations in Neonates Treated With Prolonged Whole Body Hypothermia for Hypoxic Ischemic Encephalopathy,&quot; <i>Epilepsia</i>, 2009, 50(11):2355-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19744111/pubmed\" target=\"_blank\" id=\"19744111\">19744111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filippi L, Poggi C, la Marca G, et al, &quot;Oral Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia: A Safety Study,&quot; <i>J Pediatr</i>, 2010, 157(3):361-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/20553846/pubmed\" target=\"_blank\" id=\"20553846\">20553846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glass HC, Poulin C, and Shevell MI, &quot;Topiramate For the Treatment of Neonatal Seizures,&quot; <i>Pediatr Neurol</i>, 2011, 44(6):439-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/21555055/pubmed\" target=\"_blank\" id=\"21555055\">21555055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, &ldquo;Preliminary Observations on Topiramate in Pediatric Epilepsies,&rdquo; <i>Epilepsia</i>, 1997, 38(Suppl 1):S37-41. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/ 9092958 /pubmed\" target=\"_blank\" id=\" 9092958 \"> 9092958 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, &ldquo;Topiramate Use in Pediatric Patients,&rdquo; <i>Can J Neurol Sci</i>, 1998, 25(3):S8-12. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/9706734 /pubmed\" target=\"_blank\" id=\"9706734 \">9706734 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser T, Ben-Menachem E, Bourgeois B, et al, &quot;ILAE Treatment Guidelines: Evidence-Based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy For Epileptic Seizures and Syndromes,&quot; <i>Epilepsia</i>, 2006, 47(7):1094-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16886973/pubmed\" target=\"_blank\" id=\"16886973\">16886973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, Clark PO, and McGee K, &quot;Long-Term Response to Topiramate in Patients With West Syndrome,&quot; <i>Epilepsia</i>, 2000, 41 Suppl 1:S91-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/10768309/pubmed\" target=\"_blank\" id=\"10768309\">10768309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, Clark PO, and Strawsburg R, &ldquo;A Pilot Study of Topiramate in the Treatment of Infantile Spasms,&rdquo; <i>Epilepsia</i>, 1998, 39(12):1324-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/9860068/pubmed\" target=\"_blank\" id=\"9860068\">9860068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go CY, Mackay MT, Weiss SK, et al, &quot;Evidence-Based Guideline Update: Medical Treatment of Infantile Spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society,&quot; <i>Neurology</i>, 2012, 78(24):1974-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/22689735/pubmed\" target=\"_blank\" id=\"22689735\">22689735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hershey AD, Powers SW, Vockell AL, et al, &ldquo;Effectiveness of Topiramate in the Prevention of Childhood Headaches,&rdquo; <i>Headache</i>, 2002, 42(8):810-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12390646 /pubmed\" target=\"_blank\" id=\"12390646 \">12390646 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hosain SA, Merchant S, Solomon GE, Chutorian A. Topiramate for the treatment of infantile spasms. <i>J Child Neurol</i>. 2006;21(1):17-19. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16551447/pubmed\" target=\"_blank\" id=\"16551447\">16551447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwon YS, Jun YH, Hong YJ, et al, &quot;Topiramate Monotherapy in Infantile Spasm,&quot; <i>Yonsei Med J</i>, 2006, 47(4):498-504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16941739/pubmed\" target=\"_blank\" id=\"16941739\">16941739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis D, Winner P, Saper J, et al, &quot;Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate For Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age,&quot; <i>Pediatrics</i>, 2009, 123(3):924-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19255022/pubmed\" target=\"_blank\" id=\"19255022\">19255022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahmoud AA, Rizk T, El-Bakri NK, et al, &quot;Incidence of Kidney Stones With Topiramate Treatment in Pediatric Patients,&quot; <i>Epilepsia</i>, 2011, 52(10):1890-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/21883178/pubmed\" target=\"_blank\" id=\"21883178\">21883178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mikaeloff Y, Rey E, Soufflet C, et al, &quot;Topiramate Pharmacokinetics in Children With Epilepsy Aged From 6 Months to 4 Years,&quot; <i>Epilepsia</i>, 2004, 45(11):1448-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/15509246/pubmed\" target=\"_blank\" id=\"15509246\">15509246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohman I, Sabers A, de Flon P, et al, &quot;Pharmacokinetics of Topiramate During Pregnancy,&quot; <i>Epilepsy Res</i>, 2009, 87(2-3):124-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19740626/pubmed\" target=\"_blank\" id=\"19740626\">19740626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohman I, Vitols S, Luef G, et al, &ldquo;Topiramate Kinetics During Delivery, Lactation, and in the Neonate: Preliminary Observations,&rdquo; <i>Epilepsia</i>, 2002, 43(10):1157-60. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/12366729/pubmed\" target=\"_blank\" id=\"12366729\">12366729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patsalos PN, Berry DJ, Bourgeois BF, et al, &quot;Antiepileptic Drugs &minus; Best Practice Guidelines For Therapeutic Drug Monitoring: A Position Paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies,&quot; <i>Epilepsia</i>, 2008, 49(7):1239-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/18397299/pubmed\" target=\"_blank\" id=\"18397299\">18397299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pellock JM, &ldquo;Managing Pediatric Epilepsy Syndromes With New Antiepileptic Drugs,&rdquo; <i>Pediatrics</i>, 1999, 104(5 Pt 1):1106-16. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/10545555 /pubmed\" target=\"_blank\" id=\"10545555 \">10545555 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qudexy XR (topiramate) [prescribing information]. Maple Grove, MN: Upsher-Smith; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenfeld WE, Doose DR, Walker SA, et al, &quot;A Study of Topiramate Pharmacokinetics and Tolerability in Children With Epilepsy,&quot; <i>Pediatr Neurol</i>, 1999, 20(5):339-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/10371378/pubmed\" target=\"_blank\" id=\"10371378\">10371378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachdeo RC, &ldquo;Topiramate. Clinical Profile in Epilepsy,&rdquo; <i>Clin Pharmacokinet</i>, 1998, 34(5):335-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/9592618/pubmed\" target=\"_blank\" id=\"9592618\">9592618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverstein FS and Ferriero DM, &quot;Off-Label Use of Antiepileptic Drugs For the Treatment of Neonatal Seizures,&quot; <i>Pediatr Neurol</i>, 2008, 39(2):77-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/18639748/pubmed\" target=\"_blank\" id=\"18639748\">18639748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topamax (topiramate) [prescribing information]. Titusville, NJ: Janssen Pharmaceutical, Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trokendi XR (topiramate) [prescribing information]. Rockville, MD: Supernus Pharmaceuticals, Inc; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Westin AA, Nakken KO, Johannessen SI, et al, &quot;Serum Concentration/dose Ratio of Topiramate During Pregnancy,&quot; <i>Epilepsia</i>, 2009, 50(3):480-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/19178558/pubmed\" target=\"_blank\" id=\"19178558\">19178558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winner P, Pearlman EM, Linder SL, et al, &quot;Topiramate For Migraine Prevention in Children: A Randomized, Double-Blind, Placebo-Controlled Trial,&quot; <i>Headache</i>, 2005, 45(10):1304-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topiramate-pediatric-drug-information/abstract-text/16324162/pubmed\" target=\"_blank\" id=\"16324162\">16324162</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12851 Version 256.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F229206\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F229207\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1055790\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675768\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1055783\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F229180\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F229165\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874884\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1055795\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132845\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F229201\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1055794\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F229250\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F229248\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F229187\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F229169\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25955898\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F229235\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F229174\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F229202\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F229176\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F229191\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1055789\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1055793\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F229168\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F229186\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11509771\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F229190\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F229193\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12851|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=topiramate-drug-information\" class=\"drug drug_general\">Topiramate: Drug information</a></li><li><a href=\"topic.htm?path=topiramate-patient-drug-information\" class=\"drug drug_patient\">Topiramate: Patient drug information</a></li></ul></div></div>","javascript":null}